Results 121 to 130 of about 11,390 (145)
Some of the next articles are maybe not open access.
Expert Opinion on Investigational Drugs, 2002
Fulvestrant, a novel oestrogen receptor (ER) downregulator, is a pure anti-oestrogen which completely blocks the trophic actions of oestrogens without exerting any partial agonist effects. It reduces expression of oestrogen receptor, progesterone receptor and proliferative and cell turnover indices. The drug is well-tolerated with minimal systemic side
Kwok Leung, Cheung, John F R, Robertson
openaire +2 more sources
Fulvestrant, a novel oestrogen receptor (ER) downregulator, is a pure anti-oestrogen which completely blocks the trophic actions of oestrogens without exerting any partial agonist effects. It reduces expression of oestrogen receptor, progesterone receptor and proliferative and cell turnover indices. The drug is well-tolerated with minimal systemic side
Kwok Leung, Cheung, John F R, Robertson
openaire +2 more sources
Hospital Pharmacy, 2002
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Dominic A. Solimando, J. Aubrey Waddell
openaire +1 more source
The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Dominic A. Solimando, J. Aubrey Waddell
openaire +1 more source
DMW - Deutsche Medizinische Wochenschrift, 2006
S, Roth, S, Schaad, V, Hardel, U, Jaehde
openaire +2 more sources
S, Roth, S, Schaad, V, Hardel, U, Jaehde
openaire +2 more sources